ArticleOncogene2006
Gene expression profiling identifies molecular subgroups among nodal peripheral T-cell lymphomas.
Article in Oncogene, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Pathogenetic and diagnostic significance of microRNA deregulation in peripheral T-cell lymphoma not otherwise specified.Blood cancer journal · 2014Trial
- stabel: An R package for variable selection and prediction in high-dimensional cross-sectional data.Software impacts · 2026Article
- Review
- Aberrant expression of GOLM1 protects ALK+ anaplastic large cell lymphoma from apoptosis by enhancing BCL-XL stability.Blood advances · 2023Article
- Article
- Proteomic profiling identifies outcome-predictive markers in patients with peripheral T-cell lymphoma, not otherwise specified.Blood advances · 2018Article
- Molecular Insights Into Pathogenesis of Peripheral T Cell Lymphoma: a Review.Current hematologic malignancy reports · 2018Review
- The curious origins of angioimmunoblastic T-cell lymphoma.Current opinion in hematology · 2016Review
- Adult systemic anaplastic large-cell lymphoma: recommendations for diagnosis and management.Expert review of hematology · 2016Review
- Article
- Clinical analysis and prognostic significance of L-asparaginase containing multidrug chemotherapy regimen in incipient peripheral T-cell lymphoma.International journal of clinical and experimental medicine · 2015Article
- Article
- Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma.Blood · 2014Article
- Molecular genetics of peripheral T-cell lymphomas.International journal of hematology · 2014Review
- From empiric to mechanism-based therapy for peripheral T cell lymphoma.International journal of hematology · 2014Review
- CD30-positive peripheral T-cell lymphomas share molecular and phenotypic features.Haematologica · 2013Article
- Loss of TCR-beta F1 and/or EZRIN expression is associated with unfavorable prognosis in nodal peripheral T-cell lymphomas.Blood cancer journal · 2013Article
- Peripheral T-cell and NK-cell lymphomas in the WHO classification: pearls and pitfalls.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2013Review
- Identification of multiple subclones in peripheral T-cell lymphoma, not otherwise specified with genomic aberrations.Cancer medicine · 2012Article
- New molecular insights into peripheral T cell lymphomas.The Journal of clinical investigation · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The classification of peripheral T-cell lymphomas (PTCL) is still a matter of debate. To establish a molecular classification of PTCL, we analysed 59 primary nodal T-cell lymphomas using cDNA microarrays, including 56 PTCL and three T-lymphoblastic lymphoma (T-LBL). The expression profiles could discriminate angioimmunoblastic lymphoma, anaplastic large-cell lymphoma and T-LBL. In contrast, cases belonging to the broad category of 'PTCL, unspecified' (PTCL-U) did not share a single molecular profile. Using a multiclass predictor, we could separate PTCL-U into three molecular subgroups called U1, U2 and U3. The U1 gene expression signature included genes known to be associated with poor outcome in other tumors, such as CCND2. The U2 subgroup was associated with overexpression of genes involved in T-cell activation and apoptosis, including NFKB1 and BCL-2. The U3 subgroup was mainly defined by overexpression of genes involved in the IFN/JAK/STAT pathway. It comprised a majority of histiocyte-rich PTCL samples. Gene Ontology annotations revealed different functional profile for each subgroup. These results suggest the existence of distinct subtypes of PTCL-U with specific molecular profiles, and thus provide a basis to improve their classification and to develop new therapeutic targets.
Indexed as
Identifiers
16288225What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.